MRP2: The Multidrug Resistance-Associated Protein 2 and Its Role in Drug Transport and Liver Health

MRP2 in Context: An Overview of a Critical ABC Transporter

MRP2, formally known as ABCC2, is a prominent member of the ATP-binding cassette (ABC) transporter family. This transporter sits on the canalicular membranes of hepatocytes, as well as on other epithelial surfaces, where it drives the active efflux of a wide array of organic anions and drug conjugates. In clinical pharmacology and hepatology alike, MRP2 is recognised as a key gatekeeper that helps to remove toxins, bile acids, conjugated bilirubin, and xenobiotics from cells into bile or urine. Understanding MRP2 is essential for comprehending how the body handles medicines, how drug–drug interactions arise, and why certain inherited disorders emerge when MRP2 function is compromised.

Where MRP2 Works: Cellular Localisation and Tissue Distribution

MRP2 is predominantly located on the apical (canalicular) membranes of hepatocytes, enabling the secretion of organic anions into bile. This action plays a crucial role in the final step of hepatic excretion for many substances, including glucuronide and sulfate conjugates. Beyond the liver, MRP2 is found in the kidney tubular cells and enterocytes of the intestine, where it contributes to renal and intestinal excretion. The broad tissue distribution means MRP2 influences pharmacokinetics and disposition of drugs and endogenous compounds across multiple organ systems, shaping both efficacy and safety profiles.

Hepatic role: canalicular bile excretion

In the liver, MRP2 partners with other canalicular transporters to export bilirubin conjugates and various drug conjugates into bile. When functioning optimally, this transporter supports smooth biliary turnover, helping to maintain bilirubin homeostasis and protect hepatocytes from toxic buildup. Disruptions in MRP2 activity can impede bilirubin excretion, with clinical consequences that range from mild perturbations to pronounced hyperbilirubinaemia in certain genetic conditions.

Intestinal and renal functions

Within the intestine, MRP2 contributes to the luminal efflux of conjugates, affecting the oral bioavailability of some medications. In the kidney, MRP2 participates in the secretion of organic anions into the urine, aiding detoxification and clearance. The cumulative effect across tissues means MRP2 can influence systemic exposure to drugs, particularly those that undergo extensive conjugation reactions, such as glucuronidation, and subsequently rely on transporter-mediated excretion.

Genetics and Variations: ABCC2 and MRP2 Function

The MRP2 transporter is encoded by the ABCC2 gene. Genetic variation in ABCC2 can modulate transporter expression, trafficking to the cell surface, and substrate specificity. Some individuals carry variants that diminish MRP2 activity, potentially altering drug clearance, bilirubin handling, and susceptibility to drug-induced toxicity. Conversely, certain promoter or coding region polymorphisms may upregulate expression or change regulatory responses, affecting how quickly substrates are expelled from cells. Clinically, these genetic differences can help explain interindividual variability in drug response and in the presentation of hereditary conditions linked to MRP2 dysfunction.

ABCC2 and disease risk: a closer look

Mutations that reduce MRP2 function are classically associated with particular inherited syndromes affecting bilirubin metabolism. When MRP2 is deficient or mislocalised, direct (conjugated) bilirubin clearance into bile is impaired, leading to elevated serum levels and, in severe cases, clinical jaundice. While these conditions are rare, they underscore the pivotal role MRP2 plays in hepatic excretory pathways. Researchers continue to investigate how subtler ABCC2 variants might influence susceptibility to cholestasis, drug-induced liver injury, and complex metabolic disorders.

MRP2 in Health: How It Protects the Body

MRP2 acts as a vital guardian against cellular accumulation of toxins and pharmacological by-products. By transporting a broad spectrum of substrates—ranging from endogenous metabolites to xenobiotics—MRP2 supports cellular detoxification and helps maintain tissue homeostasis. Its activity complements other efflux pumps and conjugation enzymes, forming an integrated network that ensures harmful compounds do not persist within hepatocytes, renal cells, or intestinal epithelium. This protective function is especially important during exposure to potentially harmful substances, including certain chemotherapeutic agents and environmental chemicals.

MRP2 and Disease: When the Transporter is Impaired

When MRP2 function is compromised, clinical consequences can arise that reflect impaired excretion. In hepatocytes, reduced MRP2 activity can slow the export of conjugated bilirubin and drug conjugates, contributing to cholestatic features or drug-induced liver injury in susceptible individuals. In patients with specific ABCC2 mutations, conjugated hyperbilirubinaemia can emerge, sometimes in conjunction with episodes of jaundice. The interplay between MRP2 deficiency and other transporters or metabolic pathways further modulates disease expression and severity.

Dubin–Johnson syndrome and Rotor syndrome

Two classical inherited conditions are frequently discussed in relation to MRP2: Dubin–Johnson syndrome and Rotor syndrome. Dubin–Johnson syndrome results from markedly reduced MRP2 activity in the liver, leading to conjugated hyperbilirubinaemia with relatively darkly pigmented liver tissue. Rotor syndrome, which has overlapping features but involves different regulatory disruptions, presents with similar yet distinct bilirubin handling patterns. Both conditions highlight the central role of MRP2 in biliary excretion and bilirubin homeostasis, and they offer valuable insights into how transporter defects manifest clinically.

MRP2 and Pharmacology: Drug Transport and Resistance

MRP2 plays a decisive part in pharmacokinetics, particularly for drugs that undergo conjugation before elimination. By actively transporting glucuronide, sulfate, and glutathione conjugates, MRP2 shapes the bioavailability and clearance of a wide range of medicines. This transporter can influence both therapeutic efficacy and adverse effects, especially in regimens that involve drugs with narrow therapeutic windows or those prone to enterohepatic recirculation.

MRP2 substrates and inhibitors

Substrates of MRP2 include many anticancer agents, antivirals, anti-inflammatory drugs, and statins, among others. The transporter’s ability to recognise and move conjugates means it can affect the disposition of poorly soluble or highly polar drug metabolites. Inhibitors of MRP2, whether clinical or inadvertent, can raise systemic exposure to substrates, potentially heightening toxicity. Conversely, inducers or activators of MRP2 expression and activity may promote faster clearance and lower drug concentrations at their targets. This dynamic underscores the importance of considering MRP2 status during drug development and in personalised medicine strategies.

Drug interactions and clinical implications

Co-administration of medications that compete for MRP2 transport or alter its expression can lead to clinically meaningful interactions. For example, a drug that strongly inhibits MRP2 may increase the exposure of another drug that relies on MRP2 for elimination, raising the risk of adverse events. Healthcare professionals increasingly recognise the need to account for transporter-mediated interactions alongside hepatic metabolism and renal clearance when designing safe and effective regimens. Knowledge of MRP2 function thus supports better dosing decisions and mitigates the risk of hepatobiliary toxicity.

MRP2 in Research and Drug Development

In the laboratory, MRP2 serves as a model system for studying transporter biology and drug resistance. Researchers employ cellular assays that measure ATP-dependent transport activity, substrate specificity, and trafficking to the cell surface to understand how mutations or regulatory changes influence function. These studies inform drug screening, helping to predict whether new chemical entities might be substrates or inhibitors of MRP2. The data also guide safety assessments and the selection of lead compounds with favourable excretion profiles, ultimately shaping successful drug development programs.

In vitro assays and biomarker potential

Experimental approaches such as transfected cell lines, vesicular transport assays, and reporter systems enable precise measurement of MRP2 activity. These tools help quantify transporter capacity, substrate affinity, and the impact of genetic variants. In clinical settings, researchers explore whether MRP2 activity markers in blood or bile could serve as biomarkers for liver function, transporter integrity, or the likelihood of drug-induced cholestasis. While still an area of active investigation, the concept holds promise for refining personalised therapies.

Future Directions: Personalised Medicine and Beyond

The study of MRP2 is moving increasingly towards personalised medicine. As we gain a clearer picture of how ABCC2 variants influence drug handling, clinicians may tailor therapy based on a patient’s transporter genotype. Such precision could optimise dosing, improve efficacy, and reduce toxicity for medications that are transporter-sensitive. Additionally, environmental and nutritional factors that modulate MRP2 expression — and thus transporter capacity — may become important considerations in holistic patient care. Ongoing research into MRP2 regulation, interaction with other transporters, and cross-species differences continues to illuminate how this transporter integrates into human physiology and disease management.

MRP2: A Central Player in Liver Health and Pharmacology

From its fundamental role in canalicular excretion to its influence on drug disposition and disease risk, MRP2 stands as a cornerstone of hepatic pharmacology and clinical medicine. By transporting conjugated metabolites into bile or urine, MRP2 supports detoxification, protects hepatic tissue, and shapes how medicines behave inside the body. The ABCC2 gene and its protein product exemplify how a single molecular transporter can exert wide-ranging effects across organ systems, impacting everything from bilirubin metabolism to the success of chemotherapeutic regimens. As science advances, the story of MRP2 will continue to unfold, guiding safer drugs, smarter therapies, and more effective strategies for managing liver and biliary health.

The practical takeaways for clinicians and researchers

For clinicians, recognising MRP2’s role helps explain individual variations in drug response and bilirubin handling. When patients exhibit unexpected drug toxicity or unusual bilirubin levels, transporter genetics may be a contributing factor to consider alongside metabolic enzymes. For researchers and pharmaceutical developers, MRP2 remains a critical consideration in drug design and safety assessment. By anticipating how new compounds interact with MRP2, teams can reduce late-stage failures and improve the therapeutic index of medications. In every scenario, MRP2 serves as a reminder of the intricate interplay between genetics, physiology, and pharmacology that underpins modern medicine.